Related Announcements

PAR-20-084 - NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

This Notice serves to clarify eligibility criteria regarding foreign components in the following section of Funding Opportunity Announcement PAR-20-084, "NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)". This change will apply beginning March 16^th, 2022, for Renewals/Revisions/Resubmissions; and apply for new applications beginning June 16^th, 2022.

Currently Reads:

Part 2. Full Text of Announcement

Section III. Eligibility Information

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Modified to Read (changes shown in bold italics):

Part 2. Full Text of Announcement

Section III. Eligibility Information

Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Randy King, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-0707
Email: Randy.King@nih.gov